A comparison of extended-spectrum beta-lactamide (ESBL)–producing *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infections in Alberta using a provincial surveillance system

Kathryn R. Bush MSc1, Jennifer Ellison MSc1, Kaitlin Hearn BEH(AD)1,2, Ted Pfister MSc1 and Geoffrey Taylor MD1,2

1Infection Prevention and Control, Alberta Health Services, Alberta and 2Department of Medicine, University of Alberta, Edmonton, Alberta

To the Editor—The recent study by Scheuerman *et al* investigating risk factors associated with extended-spectrum β-lactamide (ESBL)–producing *Escherichia coli* and ESBL-producing *Klebsiella pneumoniae* bloodstream infections was of interest to our group and spurred further investigation into local infection prevention and control surveillance data. Data were collected prospectively from acute care facilities within Alberta. The data were retrospectively analyzed for factors comparable to Scheuerman *et al* including gender, age, case classification, time from admission to positive culture, and source of secondary infection. The data reflect all ESBL bloodstream infection cases in Alberta from April 2013 to March 2018, and our results are similar to the findings of Scheuerman *et al*. (Table 1)

Of 593 ESBL isolates, 551 (93%) were *E. coli*. Of the cases that were extracted from our database, a statistically significant higher proportion of ESBL-producing *K. pneumoniae* bloodstream infections were classified as hospital acquired or healthcare associated with a longer average time from admission to culture than bloodstream infections with ESBL-producing *E. coli*. Conversely, a statistically significant higher proportion of ESBL *E. coli* bloodstream infection cases were noted to be community-acquired; only 19% of *Klebsiella* isolates were considered community-acquired.

The results obtained within Alberta are similar to the findings of Scheuerman *et al*. Going forward, future investigations may provide additional clarity on the differences between ESBL-producing isolates based on further study of clinical and nonclinical parameters, including the proportion of nonurine ESBL-producing *E. coli* isolates compared to ESBL-producing *K. pneumoniae* isolates, the appropriateness of initial antimicrobial therapy, and the travel history of patients with ESBL infections.

**Author ORCIDs.** Kaitlin Hearn, 0000-0002-8201-7986


**Acknowledgments.** We acknowledge the infection control professionals and physicians of Alberta Health Services and Covenant Health for these surveillance data.

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**Reference**